Guggenheim Maintains Buy on Spyre Therapeutics, Raises Price Target to $130

Benzinga · 1d ago
Guggenheim analyst Yatin Suneja maintains Spyre Therapeutics (NASDAQ:SYRE) with a Buy and raises the price target from $115 to $130.